OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) — Market Cap & Net Worth
Market Cap & Net Worth: OUTLOOK THERAPEUTICS INC (OTLK)
OUTLOOK THERAPEUTICS INC (NASDAQ:OTLK) has a market capitalization of $36.02 Million ($36.02 Million) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23065 globally and #4985 in its home market, demonstrating a -25.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OUTLOOK THERAPEUTICS INC's stock price $0.98 by its total outstanding shares 73509455 (73.51 Million). See OUTLOOK THERAPEUTICS INC (OTLK) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
OUTLOOK THERAPEUTICS INC Market Cap History: 2016 to 2026
OUTLOOK THERAPEUTICS INC's market capitalization history from 2016 to 2026. Data shows change from $35.40 Billion to $71.82 Million (-47.60% CAGR).
Index Memberships
OUTLOOK THERAPEUTICS INC is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.00% | #655 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #2185 of 3165 |
Weight: OUTLOOK THERAPEUTICS INC's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
OUTLOOK THERAPEUTICS INC Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OUTLOOK THERAPEUTICS INC's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
OUTLOOK THERAPEUTICS INC's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $35.40 Billion | $2.98 Million | -$53.30 Million | 11879.92x | N/A |
| 2017 | $15.29 Billion | $3.81 Million | -$38.85 Million | 4011.01x | N/A |
| 2018 | $5.88 Billion | $3.09 Million | -$30.09 Million | 1904.39x | N/A |
| 2019 | $867.41 Million | $8.15 Million | -$34.52 Million | 106.48x | N/A |
| 2020 | $1.91 Billion | $5.85 Million | -$35.24 Million | 326.51x | N/A |
| 2024 | $138.93 Million | $170.12K | -$75.37 Million | 816.66x | N/A |
| 2025 | $116.14 Million | $1.41 Trillion | -$62.42 Million | 0.00x | N/A |
Competitor Companies of OTLK by Market Capitalization
Companies near OUTLOOK THERAPEUTICS INC in the global market cap rankings as of August 3, 2026.
Key companies related to OUTLOOK THERAPEUTICS INC by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
OUTLOOK THERAPEUTICS INC Historical Marketcap From 2016 to 2026
Between 2016 and today, OUTLOOK THERAPEUTICS INC's market cap moved from $35.40 Billion to $ 71.82 Million, with a yearly change of -47.60%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $71.82 Million | -38.16% |
| 2025 | $116.14 Million | -16.40% |
| 2024 | $138.93 Million | -76.02% |
| 2023 | $579.25 Million | -63.52% |
| 2022 | $1.59 Billion | -20.59% |
| 2021 | $2.00 Billion | +4.62% |
| 2020 | $1.91 Billion | +120.34% |
| 2019 | $867.41 Million | -85.25% |
| 2018 | $5.88 Billion | -61.54% |
| 2017 | $15.29 Billion | -56.81% |
| 2016 | $35.40 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 3rd, 2026 the market cap of OUTLOOK THERAPEUTICS INC was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $36.02 Million USD |
| MoneyControl | $36.02 Million USD |
| MarketWatch | $36.02 Million USD |
| marketcap.company | $36.02 Million USD |
| Reuters | $36.02 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OUTLOOK THERAPEUTICS INC
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other … Read more